Adaptive Biotechnologies Corporation (ADPT): Price and Financial Metrics

Adaptive Biotechnologies Corporation (ADPT): $2.40

0.06 (+2.56%)

POWR Rating

Component Grades








Add ADPT to Watchlist
Sign Up

Industry: Biotech




#133 of NR

in industry

ADPT Price/Volume Stats

Current price $2.40 52-week high $9.08
Prev. close $2.34 52-week low $2.28
Day low $2.28 Volume 2,341,500
Day high $2.48 Avg. volume 1,616,838
50-day MA $3.37 Dividend yield N/A
200-day MA $4.84 Market Cap 348.22M

ADPT Stock Price Chart Interactive Chart >

Adaptive Biotechnologies Corporation (ADPT) Company Bio

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

ADPT Latest News Stream

Event/Time News Detail
Loading, please wait...

ADPT Latest Social Stream

Loading social stream, please wait...

View Full ADPT Social Stream

Latest ADPT News From Around the Web

Below are the latest news stories about Adaptive Biotechnologies Corp that investors may wish to consider to help them evaluate ADPT as an investment opportunity.

Adaptive Biotechnologies Corporation 2021 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Adaptive Biotechnologies Corporation in conjunction with their 2021 Q3 earnings call....

SA Transcripts on Seeking Alpha | November 4, 2021

Adaptive Biotechnologies EPS beats by $0.03, beats on revenue

Adaptive Biotechnologies (NASDAQ:ADPT): Q3 GAAP EPS of -$0.40 beats by $0.03. Revenue of $39.5M (+50.2% Y/Y) beats by $2.87M. Press Release...

Seeking Alpha | November 3, 2021

Read More 'ADPT' Stories Here

ADPT Price Returns

1-mo -25.93%
3-mo -43.40%
6-mo -48.83%
1-year -72.06%
3-year -94.48%
5-year N/A
YTD -51.02%
2023 -35.86%
2022 -72.77%
2021 -52.55%
2020 97.63%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!